CytomX Therapeutics Inc (CTMX) Q1 2025 Earnings Report

CytomX Therapeutics reported QQ1 2025 revenue of $50.92 million, marking a 22.8% year-over-year increase and a 33.66% sequential (quarterly) uptick. The gross profit aligns with revenue (gross profit of $50.92 million on revenue of $50.92 million), yielding a very high margin profile for the quarter. Operating income rose to $22.62 million, supported by EBITDA of $23.01 million and a net income of $23.53 million, translating to an EPS of $0.27. The company generated negative operating cash flow of $21.04 million and free cash flow of $21.16 million, largely driven by working capital movements (notably a sizable net change in working capital of approximately -$47.59 million). Despite near-term cash burn, CytomX finished the period with substantial liquidity: cash and cash equivalents of about $47.60 million and short-term investments of roughly $32.28 million, for total liquid assets near $79.89 million, and a net debt position of approximately -$39.45 million. Deferred revenue remains a meaningful liquidity and revenue timing component (current portion $33.23 million; non-current portion $16.21 million), highlighting collaboration-based revenue recognition dynamics. The balance sheet shows total assets of $98.50 million and total liabilities of $73.45 million, with stockholders’ equity of $25.05 million and a large accumulated deficit reflected in retained earnings of -$668.05 million. Management commentary across the quarter emphasized pipeline progress and collaboration-driven revenue, though formal forward guidance was not disclosed in the provided materials. The competitive and regulatory backdrop in oncology remains challenging, but CytomX’s cash runway and Probody platform position the company to pursue value-enhancing milestones and data readouts in its ongoing programs.